Conclusion:Our case report opens an interesting therapeutic field for the use of complement blockers for the treatment of C3G.From this point-of view, the current case report , shows that iptacopan is highly effective regarding the reduction of proteinuria and recovery and stabilization of kidney function and is well tolerated.Our case report suggests that even under the 10-month monotherapy, iptacopan may become a promising oral treatment option for C3G.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Kitamura et al. (Wed,) studied this question.